Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago , Chicago, Illinois.
Department of Pharmacology, University of Illinois at Chicago , Chicago, Illinois.
Am J Physiol Lung Cell Mol Physiol. 2018 Mar 1;314(3):L461-L472. doi: 10.1152/ajplung.00057.2017. Epub 2017 Nov 22.
Sphingosine kinase 1 (SphK1) upregulation is associated with pathologic pulmonary vascular remodeling in pulmonary arterial hypertension (PAH), but the mechanisms controlling its expression are undefined. In this study, we sought to characterize the regulation of SphK1 expression by micro-RNAs (miRs). In silico analysis of the SphK1 3'-untranslated region identified several putative miR binding sites, with miR-1-3p (miR-1) being the most highly predicted target. Therefore we further investigated the role of miR-1 in modulating SphK1 expression and characterized its effects on the phenotype of pulmonary artery smooth muscle cells (PASMCs) and the development of experimental pulmonary hypertension in vivo. Our results demonstrate that miR-1 is downregulated by hypoxia in PASMCs and can directly inhibit SphK1 expression. Overexpression of miR-1 in human PASMCs inhibits basal and hypoxia-induced proliferation and migration. Human PASMCs isolated from PAH patients exhibit reduced miR-1 expression. We also demonstrate that miR-1 is downregulated in mouse lung tissues during experimental hypoxia-mediated pulmonary hypertension (HPH), consistent with upregulation of SphK1. Furthermore, administration of miR-1 mimics in vivo prevented the development of HPH in mice and attenuated induction of SphK1 in PASMCs. These data reveal the importance of miR-1 in regulating SphK1 expression during hypoxia in PASMCs. A pivotal role is played by miR-1 in pulmonary vascular remodeling, including PASMC proliferation and migration, and its overexpression protects from the development of HPH in vivo. These studies improve our understanding of the molecular mechanisms underlying the pathogenesis of pulmonary hypertension.
丝氨酸磷酸激酶 1(SphK1)的上调与肺动脉高压(PAH)中的病理性肺血管重塑有关,但控制其表达的机制尚不清楚。在这项研究中,我们试图描述 SphK1 表达受 microRNAs(miRs)调控的机制。对 SphK1 3'-非翻译区进行计算机分析,确定了几个可能的 miR 结合位点,其中 miR-1-3p(miR-1)是最具预测性的靶标。因此,我们进一步研究了 miR-1 在调节 SphK1 表达中的作用,并描述了其对肺动脉平滑肌细胞(PASMCs)表型和体内实验性肺动脉高压发展的影响。我们的研究结果表明,miR-1 在 PASMCs 中受到缺氧的下调,并且可以直接抑制 SphK1 的表达。在人 PASMCs 中过表达 miR-1 可抑制基础和缺氧诱导的增殖和迁移。PAH 患者的 PASMCs 中 miR-1 的表达降低。我们还证明,在实验性缺氧介导的肺动脉高压(HPH)期间,miR-1 在小鼠肺组织中下调,与 SphK1 的上调一致。此外,体内给予 miR-1 模拟物可预防小鼠 HPH 的发生,并减轻 PASMCs 中 SphK1 的诱导。这些数据揭示了 miR-1 在调节缺氧时 PASMCs 中 SphK1 表达的重要性。miR-1 在包括 PASMC 增殖和迁移在内的肺血管重塑中起着关键作用,其过表达可防止体内 HPH 的发生。这些研究增进了我们对肺动脉高压发病机制的分子机制的理解。